With multidrug resistant (MDR) Enterobacteriales on the rise, a non-toxic agent with a unique 23 mechanism of action such as fosfomycin seems attractive. However, establishing accurate 24 fosfomycin susceptibility testing for non-E. coli in a clinical microbiology laboratory remains 25 problematic. We evaluated fosfomycin susceptibility by multiple methods with multiple strains 26 and species of KPC-producing clinical isolates collected at a single center between 2008 and 27 2016. In addition, we assessed the presence of fosfomycin resistance genes from whole genome 28 sequencing (WGS) data using NCBI's AMRFinder and custom HMM search. Susceptibility 29 testing was performed using glucose-6-phosphate supplemented fosfomycin E-Test and Kirby- 30 Bauer disk diffusion (DD) assays, and compared to agar dilution. Clinical Laboratory and 31 Standards Institute (CLSI) breakpoints for E. coli were applied for interpretation. Overall, 63% 32 (60/96) of isolates were susceptible by E-Test, 70% (67/96) by DD, and 88% (84/96) by agar 33 dilution. FosA was detected in 80% (70/88) of previously sequenced isolates, with species-34 specific associations and alleles, and fosA-positive isolates were associated with higher MIC 35 distributions. Disk potentiation testing was performed using sodium phosphonoformate to 36 inhibit fosA and showed significant increases in the zone diameter of DD testing for isolates that 37 were fosA-positive compared to fosA-negative. The addition of sodium phosphonoformate (PPF) 38 corrected 10/14 (71%) major errors in categorical agreement with agar dilution. Our results 39 indicate that fosA influences the inaccuracy of susceptibility testing by methods readily available 40 in a clinical laboratory when compared to agar dilution. Further research is needed to determine 41 the impact of fosA on clinical outcomes. 42 48 pathogens. Fosfomycin, which was originally discovered in 1969, has been shown to have in 49 vitro activity against CPE (3). In the United States, the oral formulation is available for the 50 treatment of uncomplicated urinary tract infections due to susceptible strains of Escherichia 51 coli and Enterococcus feacalis. Outside of the United States, the intravenous (IV) formulation is 52 approved and available for the management of systemic infections (4). Zavante Pharmaceuticals 53 received Fast Track designation from the FDA in 2015 for IV fosfomycin and have completed 54 Phase III clinical trials for the United States market (5).
Introduction 43
Antimicrobial resistance among gram-negative organisms continues to increase and presents a 44 serious threat to modern medicine with carbapenemase-producing Enterobacteriaceae (CPE) 45 considered one of the most pressing issues (1). The concern with CPE is largely due to a lack of 46 remaining therapeutic options, especially oral agents (2). This has led to the re-evaluation of older antimicrobials to combat infections due to multidrug-resistant (MDR) Gram supplemented with 50µg G6P. The plates were incubated overnight at 37 0 C and the inhibition 122 zone was recorded. These inhibition zones were then compared the DD inhibition zones of 123 fosfomycin without the supplementation of PPF. For each isolate tested, a blank disk with PPF 124 was also placed on the agar plate to serve as a negative control.
125
Molecular mechanisms of resistance to fosfomycin were investigated in a subset of isolates 126 previously whole genome sequenced by Ilumina Sequencing (HiSeq, 2000) as previously 127 described (20). The quality filtered short reads were de novo assembled using SPAdes v3.11 128 (23), and the contigs were screened for fos resistance genes using NCBI's AMRFiner (id > 0.9; 129 cov > 0.5)(24). For isolates where AMRFinder failed to detect fos genes, we screened the 130 contigs using a custom HMM model built from distinct fosA protein sequences published by Ito without fosA (n=18) had a MIC range of ≤0.5 to 1024 µg/mL, MIC 50 of ≤0.5 µg/mL, and MIC 90 155 of 2 µg/mL. One of the 18 isolates (5.56%) was non-suseptible to fosfomycin. Isolates 156 harboring fosA (n=70) had a MIC range of ≤0.5 to >1024 µg/mL, MIC 50 of 16 µg/mL, and MIC 90 157 of 128 µg/mL. Eleven of the 70 isolates (16%) were non-susceptible to fosfomycin. Isolates 158 carrying the fosA gene were associated with a higher MIC distribution as compared to those 159 without the gene (P=<0.00001), but did not differ in rates of non-susceptibility (P=0.26). These 160 results are shown in Table 3 .
161

FosA inhibition effect on Susceptibility Testing by Diffusion Method
162
Disk potentiation testing with PPF was performed on all 96 isolates. Categorical agreement with 163 agar dilution was found in 72/96 (75%) of isolates prior to the additional of PPF and in 81/96 164 (84%) isolates after the addition of PPF (p=0.11). In the 88 isolates with WGS available, rates of 165 categorical agreement were compared with and without PPF. In isolates that were negative for 166 the fosA gene, categorical agreement was found in 18/18 (100%) and 17/18 (94%) of isolates 167 before and after the additional of PPF, respectively (p=1). In isolates that carried the fosA gene, 168 categorical agreement was found in 49/70 (70%) and 59/70 (84%) before and after the addition 169 of PPF, respectively (p=0.04). When specifically isolating all non-susceptible isolates by DD, 170 categorical agreement was found in 9/31 (29%) isolates and 20/31 (65%) before and after the 171 addition of PPF, respectively (p=0.005). Results are shown in Table 4 and Table 5 . The 172 presence of PPF not only increased the zone size but also greatly decreased the presence of 173 colonies within the zone in DD testing for the fosA-positive isolates (Figure 2) . 174 175 We demonstrate that fosfomycin susceptibility testing by routinely used laboratory diffusion-178 based methods (E-test and DD) largely overcalls resistance, when compared to agar dilution as a 179 gold standard (see Table 1 ). Fosfomycin susceptibility appears to be influenced by the presence 180 of fosA among these KPC-producing Enterobacteriales isolates. This is highly relevant to the 181 clinical microbiologist who is frequently fielding requests for fosfomycin susceptibility testing 182 for non-E. coli Enterobacteriales. A prior study by susceptible Enterobacteriaceae isolates, of which 80 produced various carbapenemases (KPC, 184 VIM, NDM, OXA-48) and similarly found 81% of isolates to be susceptible to fosfomycin with 185 a MIC of ≤64 mcg/mL by agar dilution. This study also found similar issues of discordance with 186 diffusion testing methods (15), as was also seen in Hirsch et al. (14) . This decision for the former was based on the findings that sub-colonies of E. coli within 200 inhibition zones are rare (<1% of isolates) and largely less fit with channel or transporter 201 mutations (8, 9) . 202 We postulate based on our findings that the colonies within the inhibition zone seen more 203 frequently with some non-E. coli species may be driven by the presence of a chromosomal fosA 204 rather than channel or transporter mutations. Thus the advice to ignore the colonies in the zone 
211
In our subset of E. coli isolates (n=5), categorical agreement was found in 5 of 5 (100%) isolates.
212
All E. coli isolates were susceptible to fosfomycin by both DD and agar dilution, and no colonies 213 were observed within the zones of inhibition. Although our numbers are small, this is consistent 214 with other reports (8).
215
FosA (alleles 1-7) was identified in the majority of the clinical isolates in this study. FosA was 216 present in all Klebsiella spp. isolates, with a large portion harboring the fosA6 allele. FosA6 was 217 first reported in 2016, from an ESBL-producing, fosfomycin-resistant E. coli strain in 218 Pennsylvania, USA. It shared 96% identity with fosA5 and 79% identity with fosA3 but was 219 located on a plasmid, unlike the chromosomally-encoded fosA in K. pneumoniae (30). It has 220 been suggested that fosA6 was mobilized from the chromosome of K. pneumoniae to an E. coli 221 plasmid (30). However, in our study, no E. coli harbored fosA6, but rather one isolate harbored significant MIC reductions and restored fosfomycin susceptibility in fosA-positive Gram-246 negative organisms (29). PPF is available as the antiviral foscarnet but would likely be 247 unattractive as an adjuvant therapy due to toxicity.
248
Our study is limited by a small sample size of bla KPC -positive multidrug-resistant isolates 249 collected from a single center. However, the clinical utility of fosfomycin is primarily against 250 MDR isolates and our study highlights the difficulty in accurately providing fosfomycin AST for 251 these organisms. A further limitation is the lack of exploration of other molecular mechanisms 252 of resistance which were not evaluated in all isolates. Our study also lacks outcome data, and 253 therefore we can make no conclusions on the clinical implications of fosfomycin susceptibility 254 testing results.
255
In conclusion, fosfomycin appears to have reliable in vitro activity against KPC-producing 256 Gram-negative organisms by agar dilution. However, methods readily available in a clinical 257 microbiology laboratory, E-test and DD, generate frequent major errors for the same isolates, 258 with the presence of fosA impacting the interpretation of these diffusion-based methods. Caution 259 is advised when interpreting and releasing AST results derived from diffusion-based methods for 260 non-E. coli Enterobacteriales. Regardless, further research is needed to establish correlations 261 between antimicrobial susceptibility testing, fosA presence and clinical outcomes. Fosfomycin was provided and a portion of the study was funded by Zavante Therapeutics. 
